LB Pharmaceuticals (LBRX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 3, 2026, will be held virtually, allowing shareholders to vote and ask questions online; record date for voting is April 7, 2026.

• Two main proposals: election of three Class I directors for terms expiring in 2029 and ratification of BDO USA, P.C. as independent auditor for 2026.

• Proxy materials are available online, and shareholders can vote by internet, phone, mail, or during the meeting.

Voting matters and shareholder proposals

• Shareholders will vote on electing three Class I directors: Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum.

• Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Shareholders may submit proposals for the 2027 Annual Meeting by December 24, 2026, for inclusion in the proxy statement.

Board of directors and corporate governance

• Board is divided into three classes, each serving staggered three-year terms; nine members currently serve.

• Majority of directors are independent per Nasdaq standards; board leadership is separated between an independent Chair and CEO.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent members.

• Board met 17 times in 2025; all directors attended at least 75% of meetings.

• Stockholders can communicate directly with the board or committee chairs.